Personal information

No personal information available

Activities

Collapse all

Employment (2)

Renji Hospital: Shanghai, CN

2021-12-01 to present | Researcher (Department of Urology)
Employment
Source: Self-asserted source
Wei Zhai

University of Rochester Medical Center: Rochester, NY, US

2013-08-08 to 2015-06-02
Employment
Source: Self-asserted source
Wei Zhai

Education and qualifications (2)

University of Rochester Medical Center: Rochester, NY, US

2013-08-08 to 2015-06-02 | post doctor
Education
Source: Self-asserted source
Wei Zhai

Tongji University: Shanghai, CN

2010-09-01 to 2013-06-30 | Doctor (Medical Department)
Education
Source: Self-asserted source
Wei Zhai

Works (14)

Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway

Cancer Letters
2025-03 | Journal article
DOI: 10.1016/j.canlet.2025.217514
Contributors: Yizheng Xue; Tianyi Chen; Zehua Ma; Xinyuan Pu; Junyao Xu; Shuanfeng Zhai; Xinxing Du; Yiyi Ji; M Celeste Simon; Wei Zhai et al.
Source: check_circle
Crossref

ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study

European Journal of Nuclear Medicine and Molecular Imaging
2024-07 | Journal article
DOI: 10.1007/s00259-024-06672-3
Part of ISSN: 1619-7070
Part of ISSN: 1619-7089
Contributors: Qianyun Wu; Yanfei Wu; You Zhang; Yihui Guan; Gang Huang; Fang Xie; Jianjun Liu; Wei Zhai; Weijun Wei
Source: Self-asserted source
Wei Zhai

Serum and Urine Metabolic Fingerprints Characterize Renal Cell Carcinoma for Classification, Early Diagnosis, and Prognosis

Advanced Science
2024-07-08 | Journal article | Author
DOI: 10.1002/advs.202401919
Part of ISSN: 2198-3844
Part of ISSN: 2198-3844
Contributors: Xiaoyu Xu; Yuzheng Fang; Qirui Wang; Shuanfeng Zhai; Wanshan Liu; Wanwan Liu; Ruimin Wang; Qiuqiong Deng; Juxiang Zhang; Jingli Gu et al.
Source: Self-asserted source
Wei Zhai

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

Annals of Oncology
2024-02 | Journal article
DOI: 10.1016/j.annonc.2023.09.3108
Part of ISSN: 0923-7534
Contributors: X.Q. Yan; M.J. Ye; Q. Zou; P. Chen; Z.S. He; B. Wu; D.L. He; C.H. He; Xue-Yi Xue; Z.G. Ji et al.
Source: Self-asserted source
Wei Zhai

Self-Assembled Hyperbranched Gold Nanoarrays Decode Serum United Urine Metabolic Fingerprints for Kidney Tumor Diagnosis

ACS Nano
2024-01-23 | Journal article
DOI: 10.1021/acsnano.3c10717
Part of ISSN: 1936-0851
Part of ISSN: 1936-086X
Contributors: Yuning Wang; Xiaoyu Xu; Yuzheng Fang; Shouzhi Yang; Qirui Wang; Wanshan Liu; Juxiang Zhang; Dingyitai Liang; Wei Zhai; Kun Qian
Source: Self-asserted source
Wei Zhai

Loss of MIR503HG facilitates papillary renal cell carcinoma associated lymphatic metastasis by triggering NOTCH1/VEGFC signaling

International Journal of Biological Sciences
2023 | Journal article
DOI: 10.7150/ijbs.83302
Part of ISSN: 1449-2288
Contributors: Yiqiu Wang; Xinyi Zheng; Wenjie Huang; Jiayi Lu; Naiqiao Hou; Jiabao Qi; Junjie Ma; Wei Xue; Junhua Zheng; Wei Zhai
Source: Self-asserted source
Wei Zhai

Spatio-temporal heterogeneity in cancer evolution and tumor microenvironment of renal cell carcinoma with tumor thrombus

Cancer Letters
2023-09 | Journal article
DOI: 10.1016/j.canlet.2023.216350
Contributors: Sian Zhou; Junhua Zheng; Wei Zhai; Yonghui Chen
Source: check_circle
Crossref

Patient-derived organoids potentiate precision medicine in advanced clear cell renal cell carcinoma

Precision Clinical Medicine
2022-10-19 | Journal article
DOI: 10.1093/pcmedi/pbac028
Contributors: Yizheng Xue; Bingran Wang; Yiying Tao; Jun Xia; Kedi Yuan; Junhua Zheng; Wei Zhai; Wei Xue
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas

Cellular Oncology
2022-08 | Journal article
DOI: 10.1007/s13402-022-00691-8
Contributors: Jiale Zhou; Junyun Wang; Wen Kong; Jin Zhang; Xiaorong Wu; Jiwei Huang; Junhua Zheng; Yonghui Chen; Wei Zhai; Wei Xue
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

RETRACTED: Hypoxia-induced lncHILAR promotes renal cancer metastasis via ceRNA for the miR-613/206/ 1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway

Molecular Therapy
2021-10 | Journal article
DOI: 10.1016/j.ymthe.2021.05.020
Contributors: Guanghui Hu; Junjie Ma; Jin Zhang; Yonghui Chen; Huan Liu; Yiran Huang; Junhua Zheng; Yunfei Xu; Wei Xue; Wei Zhai
Source: check_circle
Crossref

Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner

Oncogene
2020-10-22 | Journal article
DOI: 10.1038/s41388-020-01455-0
Contributors: Qingbo Huang; Yin Sun; Wei Zhai; Xin Ma; Donglai Shen; Songliang Du; Bosen You; Yuanjie Niu; Chi-Ping Huang; Xu Zhang et al.
Source: check_circle
Crossref

A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma

Molecular Cancer
2019-12 | Journal article
DOI: 10.1186/s12943-019-0998-y
Contributors: Wei Zhai; Rujian Zhu; Junjie Ma; Dongkui Gong; Haimin Zhang; Jin Zhang; Yonghui Chen; Yiran Huang; Junhua Zheng; Wei Xue
Source: check_circle
Crossref

Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals

Molecular Cancer
2018-12 | Journal article
DOI: 10.1186/s12943-018-0906-x
Contributors: Wei Zhai; Saiyang Li; Jin Zhang; Yonghui Chen; Junjie Ma; Wen Kong; Dongkui Gong; Junhua Zheng; Wei Xue; Yunfei Xu
Source: check_circle
Crossref

DNA‐methylation‐mediated repression of miR‐766‐3p promotes cell proliferation via targeting SF2 expression in renal cell carcinoma

International Journal of Cancer
2017-11 | Journal article
DOI: 10.1002/ijc.30853
Contributors: Chen Chen; Sheng Xue; Jin Zhang; Wei Chen; Dongkui Gong; Jiayi Zheng; Junjie Ma; Wei Xue; Yonghui Chen; Wei Zhai et al.
Source: check_circle
Crossref

Peer review (15 reviews for 8 publications/grants)

Review activity for Advanced science. (1)
Review activity for British journal of cancer. (1)
Review activity for Cancer letters. (1)
Review activity for European urology oncology. (5)
Review activity for iScience. (2)
Review activity for Journal of experimental & clinical cancer research. (3)
Review activity for Journal of translational medicine. (1)
Review activity for Oncogene. (1)
How many people are using ORCID?